Although a seemingly inopportune acquisition appears to have cost Boston Scientific dearly, the current valuation of BSX stock may be too enticing to pass up.

Non-AI Stocks Weighing Down Stephen Mandel’s 2026 Returns and Boston Scientific Corporation (NYSE:BSX) ranks 1st on this list ...

By Kamal Choudhury and Kunal Das April 22 (Reuters) - Medical device maker Boston Scientific slashed its annual profit and ...

Boston Scientific (BSX) stock drops to 52-week low of $59.32, down 37% YTD. Analysts cut targets after guidance reduction and ...

Analysts have trimmed their fair value estimate for Boston Scientific from US$100.31 to US$95.75, a reset that anchors the ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first-quarter 2026 investor ...

On April 22, 2026, investors weigh a rare combo of earnings strength and softer long-term targets reshaping this medtech ...

CEO Mike Mahoney told investors that the lowered forecast reflects challenges for several businesses, including ...

HEART PROCEDURE SUPERIOR TO DRUGS FOR COMMON ARRHYTHMIA A minimally invasive procedure that “rewires” the heart may be a ...

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large ...

April 22 () - Medical device maker Boston Scientific cut its annual profit forecast on Wednesday, overshadowing a ...

The device maker plans to invest 75 million euros into expanding the site, with a focus on cardiovascular innovation.